News | October 17, 2022
Biocon Biologics signs licensing agreement with Yoshindo
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
This will dramatically improve timely intervention with the right experts thus ensuring significant improvement in patient’s condition management and health outcome
The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
DKSH has signed an agreement to acquire two ear care brands from Noru Pharma for Australia, New Zealand, and selected markets in Asia.
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
The requirement of blood in India is estimated to be 8.5 million to 10 million units/per year, whereas the available supply is only 7.4 million units/per year
Xi Experience centre is aimed at familiarizing and bringing awareness about robotic-assisted surgery among the surgical fraternity in the country
The move will add new global talent to Cytel’s Strategic Consulting group
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
Subscribe To Our Newsletter & Stay Updated
